Introduction
Human cells of monocytic lineage, including monocytes, macrophages, and monocyte-derived dendritic cells, play an essential role in initiating and maintaining immune responses by acting as antigen-presenting cells (APC). They process and present antigenic peptides via the major histocompatibility complex (MHC) molecules and the expression of costimulatory molecules [1, 2] . The best-characterized costimulatory molecules to date are two structurally related proteins, CD80 and CD86. Both provide costimulation to Tcells, leading to their proliferation, cytokine production, and development [2, 3] . In vivo studies using anti-CD80 and anti-CD86 monoclonal antibodies or genetically manipulated animals have demonstrated that a blockade of CD80/CD86 costimulatory molecules can prolong allograft survival and reduce the severity of autoimmune diseases [4, 5] . Preliminary clinical studies in human subjects also support this concept [6] . Therefore, pharmacological intervention in the upregulation of CD80/CD86 may therefore be useful in the treatment of autoimmune diseases or in transplantation.
Tripterygium wilfordii Hook F (TWHF) is a herb used in traditional Chinese medicine for the treatment of rheumatoid arthritis and other autoimmune diseases [7, 8] . Triptolide, a highly oxygenated diterpenoid triepoxide, is the major component responsible for the immunosuppressive and anti-inflammatory effects of TWHF [9] . It is effective for the treatment of autoimmune diseases, prevention of allograft rejection, and graft-versus-host disease in animal experiments [10] [11] [12] [13] . The inhibitory effect of triptolide on T-cell activation is stronger than cyclosporine [14] and FK-506 [15] in vitro. Furthermore, it can induce activated T-cell apoptosis [16] . Thus, T-cells are considered to be the main target for triptolide. Recently, Hong et al [17] and Li et al [18] demonstrated that triptolide inhibited upregulation of B7 on activated human proximal tubular epithelial cells. These results suggest that triptolide may have suppressive effects on APC. In a further analysis of this theory, we used a human monocytic leukemia cell line (THP-1) that had been differentiated into macrophage-like cells by treatment with Me 2 SO. The macrophage-like THP-1 cells were used to examine the influences of triptolide on the expression of CD80 and CD86 molecules and the production of IL-12, an important cytokine that biases CD4 + T-cells toward Th1 differentiation [19] . Cytokine analysis THP-1 cells were cultured in 24-well plates at 6.0×10 5 cells in 2 mL of RPMI1640 medium with 10% FBS and other treatments were the same as in the surface molecules analysis. Culture supernatants were harvested and stored at -20 o C. Human IL-12p70 and IL-12p40 productions were measured using ELISA kits (PharMingen) according to the manufacturer's instructions.
Materials and methods

Reagents
MTT assay Cytotoxicity was assessed by MTT assay [20] . Me 2 SO-differentiated THP-1 cells were incubated in a 96-well plate at 5.4×10 4 cells in 180 µL of RPMI1640 medium with 10% FBS per-well for 72 h with and without various concentrations of triptolide. MTT (5 g/L) 18 µL was added 5 h prior to the end of the culture, and then 90 µL solvent (10% SDS, 50% N, N-dimethy formamide, pH 7.2) was added. The cells were then incubated for another 7 h and value was measured at 570 nm by a microplate reader (Bio-Rad Model 550, Japan).
Statistical analysis Results were expressed as mean±SD. An independent two-tailed t-test was performed and P<0.05 was considered to be statistically significant.
Results
Triptolide influenced the surface molecule expressions on Me 2 SO-differentiated THP-1 cells THP-1 cells are known to be activated by LPS stimulation and have been used as a surrogate for investigation of human monocytes [21] . (Figure 2 ). IL-10 production was too low to be detected in this experiment system. Cytotoxicity of triptolide on Me 2 SO-differentiated THP-1 cells We examined whether the above suppressive effects of triptolide were due to its cytotoxicity to THP-1 cells. When Me 2 SO-differentiated THP-1 cells were cultured with and without different concentrations of triptolide for 72 h, the cytotoxicity was monitored by MTT assay. As shown in Figure 3 , triptolide did not exert any cytotoxic effect on the THP-1 cells from 2.5 µg/L to 0.625 µg/L in the present study.
Discussion
The immunosuppressive and therapeutic activity of triptolide upon systemic administration has been demonstrated in animal models for human-like diseases, such as in experimental autoimmune uveitis [22] , collagen-induced arthritis [11] , diabetes [12] , nephrotic syndrome [13] . It also improves the survival rate of the heart [23] and kidney [24] allograft in the rat transplantation model and graft-versus-host disease in a murine allogeneic bone marrow transplantation model [25] . However the immunosuppressive mechanism of triptolide has not been completely delineated [26] . In the present study, we demonstrated a new finding that triptolide, an active component of TWHF, directly down-regulats the costimulation molecule CD80 and CD86 expressions on macrophages-like cells (Me 2 SO-differentiated THP-1 cells), and inhibits the bioactive form of IL-12p70 production from Me 2 SO-differentiated THP-1 cells by a dose-dependent manner.
CD80 and CD86 on APC delivered the critical costimulatory signals for optimal T-cell activation [3] . Blockade of CD80 and CD86 signaling resulted in ineffective Tcell activation. The implication is that reduced and blocked CD80/CD86 costimulations can prevent the induction of pathogenic T-cell responses in autoimmune disease and allow for prolonged acceptance of allografts in organ transplantation [4] [5] [6] . In addition to the processing and presentation of antigenic peptides via MHC molecules and the expression of costimulatory molecules, APC played a central role in driving CD4 + T helper cell differentiation through the production of critical cytokines, such as IL-12, IL-10, TGF-β and possibly IL-4. The production of bioactive form IL12p70 by host antigen-presenting cells was a primary determinant in the differentiation of naive CD4 + T cells into Th1 effector cells [19] . These suppressive effects of triptolide on CD80 and CD86 expressions, and IL12p70 production suggest an important therapeutic implication for multiple sclerosis and other abnormal immune response mediated diseases associated with the increased expression of CD80/CD86 and the production of IL-12 [27] . Triptolide has been proven to be a potent immunosuppressive agent, although information on the molecular mechanism of triptolide is scarce. Recent studies have shown that triptolide inhibits T-cell activation and early cytokine gene transcription in T-cell at the purine-box/ARRE/NF-AT and NF-κB target sequence after specific DNA binding [28, 29] . NF-κB is a family of transcription factors central to immunity and inflammation. It regulates expression of a number of genes, including cytokines, costimulatory molecules, nitric oxide, and susceptibility to apoptosis [30] . Therefore, the suppressive effects of triptolide on the co-stimulatory molecular expression and IL-12 production from THP-1 cells can result from the inhibition of NF-κB transcriptional activation.
In conclusion, we have demonstrated that triptolide downregulats the levels of CD80 and CD86 expressions in THP-1 cells. Production of bioactive form IL-12p70 in THP-1 cells was effectively inhibited by triptolide. These immunosuppressive activities of triptolide contribute, at least in part, to the therapeutic effect and mechanism of triptolide in the treatment of autoimmune diseases.
